SFDA item 89 · IV. PMF/VAMF
Introduction of test for viral markers when this introduction will have significant impact on the viral risk assessment.
Variation category under SFDA, EU and US FDA rules for this change, with the variant wording as published.
SFDA Saudi Food and Drug Authority
Guidelines for Variation Requirements v6.3 (DS-G-006), item 89 — official PDF, p. 78 ↗
| Variant | Change | Type |
|---|---|---|
| - | Introduction of test for viral markers when this introduction will have significant impact on the viral risk assessment. | Type II |
EU European Union
Commission Guidelines C/2025/5045 — EUR-Lex ↗
M.14 · Introduction of test for a new viral marker when this will have significant impact on the viral risk assessment
| Variant | Change | Type |
|---|---|---|
| - | Introduction of test for a new viral marker when this will have significant impact on the viral risk assessment | Type II |
US FDA US Food and Drug Administration
21 CFR 314.70 and FDA guidance — Outside 21 CFR 314.70 — 21 CFR 610.40; 601.12
| Change | Category | Reference |
|---|---|---|
| Donor tests are set by regulation and implemented under CBER licenses | No US equivalent |
Note: Required donor tests are set by regulation (21 CFR 610.40) and implemented under the establishments' and fractionator's CBER licenses (21 CFR 601.12), not through a PMF or 21 CFR 314.70.
Other items in IV. PMF/VAMF
- 1 · Change in the marketing authorization holder
- 2 · Remove agent name from the artwork (Mock-up)
- 3 · Change in the (invented) name of the medicinal product
- 4 · Change in name of the active substance
- 5 · Change in the name and/or address of a manufacturer or supplier of the active substance, starting material, reagent or intermediate used in the manufacture of the active substance (where specified in the product dossier) where no Certificate of Suitability is available
- 6 · Change in the name and/or address of a manufacturer of the finished product, including quality control sites
- 7 · Change in ATC Code /ATC Vet Code
- 8 · Deletion of a manufacturing sites (including for an active substance, intermediate or finished product, packaging site, manufacturer responsible for batch release, site where batch control takes place, or supplier of a starting material, reagent or excipient, when mentioned in the dossier).
- 55 · Change in the summary of product characteristics, labeling and patient information leaflet of a generic/hybrid/biosimilar medicinal product following assessment of the same change for the reference product *.
- 56 · Change(s) in the summary of product characteristics, labeling and patient information leaflet related to post authorization safety study (PASS), periodic safety update report, risk management plan or SFDA drug safety monitoring activities.
- 57 · Variations related to significant modifications of the Summary of Product Characteristics due in particular to new quality, pre-clinical, clinical or pharmacovigilance data*
- 58 · Change(s) to therapeutic indication(s)
Not regulatory advice. The binding text is each regulator's current official document; confirm the category with the authority before filing. FDA publishes no classification table: the US category follows FDA guidance or, where the guidance does not name the change, the closest example under 21 CFR 314.70.